Cargando…
Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients
CD163+ M2 macrophages have been suggested to counteract tumor immunity by increasing immunosuppressive mechanisms including PD-L1 and IL-10 expression. Soluble levels of PD-L1, IL-10, and CD163 have been reported as potential biomarkers in various cancers, although the prognostic value in renal cell...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871202/ https://www.ncbi.nlm.nih.gov/pubmed/35204426 http://dx.doi.org/10.3390/diagnostics12020336 |
_version_ | 1784656940514672640 |
---|---|
author | Davidsson, Sabina Huotilainen, Sofia Carlsson, Jessica Sundqvist, Pernilla |
author_facet | Davidsson, Sabina Huotilainen, Sofia Carlsson, Jessica Sundqvist, Pernilla |
author_sort | Davidsson, Sabina |
collection | PubMed |
description | CD163+ M2 macrophages have been suggested to counteract tumor immunity by increasing immunosuppressive mechanisms including PD-L1 and IL-10 expression. Soluble levels of PD-L1, IL-10, and CD163 have been reported as potential biomarkers in various cancers, although the prognostic value in renal cell carcinoma (RCC) has to be further elucidated. In the present study, we measured the levels of sPD-L1, sIL-10, and sCD163 in 144 blood samples from patients with RCC. The levels were determined by using enzyme linked immunosorbent assays. Soluble PD-L1 and CD163 were detectable in 100% of the serum samples, and sCD163 in 22% of the urine samples, while only a minority of the samples had detectable sIL-10. Significantly higher serum levels of sPD-L1 and sCD163 were observed in patients with metastatic disease (p < 0.05). The results also showed that patients with high levels of sPD-L1 in serum had shorter cancer-specific survival compared with patients with low levels (p = 0.002). The results indicate that sPD-L1 most significantly reflects tumor progression in RCC. |
format | Online Article Text |
id | pubmed-8871202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88712022022-02-25 Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients Davidsson, Sabina Huotilainen, Sofia Carlsson, Jessica Sundqvist, Pernilla Diagnostics (Basel) Article CD163+ M2 macrophages have been suggested to counteract tumor immunity by increasing immunosuppressive mechanisms including PD-L1 and IL-10 expression. Soluble levels of PD-L1, IL-10, and CD163 have been reported as potential biomarkers in various cancers, although the prognostic value in renal cell carcinoma (RCC) has to be further elucidated. In the present study, we measured the levels of sPD-L1, sIL-10, and sCD163 in 144 blood samples from patients with RCC. The levels were determined by using enzyme linked immunosorbent assays. Soluble PD-L1 and CD163 were detectable in 100% of the serum samples, and sCD163 in 22% of the urine samples, while only a minority of the samples had detectable sIL-10. Significantly higher serum levels of sPD-L1 and sCD163 were observed in patients with metastatic disease (p < 0.05). The results also showed that patients with high levels of sPD-L1 in serum had shorter cancer-specific survival compared with patients with low levels (p = 0.002). The results indicate that sPD-L1 most significantly reflects tumor progression in RCC. MDPI 2022-01-28 /pmc/articles/PMC8871202/ /pubmed/35204426 http://dx.doi.org/10.3390/diagnostics12020336 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Davidsson, Sabina Huotilainen, Sofia Carlsson, Jessica Sundqvist, Pernilla Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients |
title | Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients |
title_full | Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients |
title_fullStr | Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients |
title_full_unstemmed | Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients |
title_short | Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients |
title_sort | soluble levels of cd163, pd-l1, and il-10 in renal cell carcinoma patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871202/ https://www.ncbi.nlm.nih.gov/pubmed/35204426 http://dx.doi.org/10.3390/diagnostics12020336 |
work_keys_str_mv | AT davidssonsabina solublelevelsofcd163pdl1andil10inrenalcellcarcinomapatients AT huotilainensofia solublelevelsofcd163pdl1andil10inrenalcellcarcinomapatients AT carlssonjessica solublelevelsofcd163pdl1andil10inrenalcellcarcinomapatients AT sundqvistpernilla solublelevelsofcd163pdl1andil10inrenalcellcarcinomapatients |